Galcanezumab: A Breakthrough in Migraine and Headache Relief

Research Summary

Galcanezumab, a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) pathway, is transforming migraine treatment with its rapid action, monthly dosing, and favorable pharmacokinetics. A review in Expert Review of Neurotherapeutics summarizes galcanezumab's role in preventing migraines, highlighting its efficacy in episodic migraines and potential benefits for cluster and medication-overuse headaches. Clinical trials and real-world studies confirm its consistent efficacy, tolerability, and convenience. Key challenges include finding biomarkers to identify responders, addressing access and cost issues, and expanding research for special populations like pediatrics and pregnant individuals. Future research should refine patient selection and explore new treatment targets.

Study Details

📄 Title: Profiling galcanezumab in episodic migraine, cluster headache, and medication overuse headache.

👥 Research Team: González-Hernández A, Ferrusca JD, Villalón CM

📚 Published In: Expert Rev Neurother

📅 Publication Date: 2026 May 25

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.